Predict your next investment

MIMETAS company logo
SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
mimetas.com

See what CB Insights has to offer

Founded Year

2013

Stage

Grant | Alive

Total Raised

$28.9M

Valuation

$0000 

About MIMETAS

MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its microfluidic technology enables testing of drug compounds in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation. MIMETAS develops and validates customised disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.

MIMETAS Headquarter Location

J.H. Oortweg 19

Leiden, 2333 CH,

Netherlands

+31 85 888 31 61

Latest MIMETAS News

MIMETAS opens Phenotypic Screening Center

Jan 10, 2022

Leiden, May 27, 2021 - MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. In contrast to other Organ-on-a-Chip platforms, the MIMETAS OrganoPlate® technology offers the scalability and the throughput needed for drug discovery studies. Image: https://www.mimetas.com

Oct 18, 2021
MIMETAS is Hiring!
Oct 11, 2021
MIMETAS is Hiring!

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MIMETAS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MIMETAS is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Digital Health

12,256 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

MIMETAS Patents

MIMETAS has filed 6 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Epithelial cells
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/5/2015

1/14/2020

Fluid dynamics, Microfluidics, Nanotechnology, Fluid mechanics, Biotechnology

Grant

Application Date

6/5/2015

Grant Date

1/14/2020

Title

Related Topics

Fluid dynamics, Microfluidics, Nanotechnology, Fluid mechanics, Biotechnology

Status

Grant

MIMETAS Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MIMETAS Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.